Planet Green Holdings

Planet Green has begun commercial operations to procure, market and distribute lactoferrin and plans to expand its leadership team with a chief scientist, a hire currently in advanced negotiations. The company uses lactoferrin as the key active ingredient in its immune chewable tablets and is targeting the growing Chinese market, which accounts for about 22% of global demand. Planet Green points to limited domestic production capacity in China, explains the complex extraction process from cow’s milk, and sees market potential from rising demand in infant formula, sports nutrition and dietary supplements. » Plus sur de.investing.com

Planet Green Holdings has completed the sale of its 100% stake in Bless Chemical (Bless HK) to Hongzhang Liang for a nominal purchase price, including the indirect disposal of subsidiary Jingshan. After the transaction, the company no longer controls Bless HK or Jingshan, and their results will no longer be consolidated. The board cited Jingshan’s discontinued operations, its financial position and a strategic focus on consumer goods and digital advertising as reasons for the move. In addition, the most recent audit report contained a going-concern warning regarding inventory, which raised doubts about continuance. » Plus sur de.investing.com

NYSE Regulation has accepted Planet Green Holdings' compliance plan and granted the company an extension through June 8, 2027, while the exchange will regularly review progress. Planet Green shows significant financial weaknesses, including negative EBITDA of -$8.53 million, a current ratio of 0.56 and a gross profit margin of 7.4%. The micro-cap company is valued at about $27.5 million and its stock trades at $2.93; if improvements do not occur, delisting proceedings may be initiated. » Plus sur de.investing.com